NEW YORK (GenomeWeb) – Cancer Genetics today said that its revenues in the second quarter rose nearly three-fold year over year, paced by a sharp spike in its biopharma services. 

The Rutherford, New Jersey-based cancer diagnostics firm reported total revenues of $4.2 million for the three months ended June 30, up from $1.5 million in the year-ago quarter. Its biopharma service business recorded $2.7 million in revenues, up from $400,000 a year ago, while its clinical service revenues rose 18 percent to $1.3 million from $1.1 million. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.